We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adolescent Mite Allergy Safety Evaluation (AMASE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04541004
Recruitment Status : Completed
First Posted : September 9, 2020
Last Update Posted : July 19, 2021
Sponsor:
Collaborator:
Syneos Health
Information provided by (Responsible Party):
ALK-Abelló A/S

Brief Summary:

This is a 28-day clinical trial studying the safety of the house dust mite tablet in adolescents with allergic rhinitis/rhinoconjunctivitis.

The purpose of this trial is to collect additional safety information about a tablet used to treat house dust mite allergies, when used to treat adolescents who have these allergies.

The trial medication used is already approved to treat allergic rhinitis caused by house dust mite in adults and adolescents (12-17 years old) in several countries.


Condition or disease Intervention/treatment Phase
Allergic Rhinitis Allergic Rhinoconjunctivitis Biological: HDM SLIT-tablet Phase 3

Detailed Description:
This trial is a 28-day, single-arm open-label phase III trial to evaluate safety of the house dust mite SLIT-tablet in adolescents (12-17 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma. Approximately 250 adolescents will be enrolled in the trial and will receive the house dust mite SLIT tablet. The trial is conducted in several European countries.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 254 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: single-armed
Masking: None (Open Label)
Masking Description: Non applicable
Primary Purpose: Treatment
Official Title: A 28-day, Single-armed, Open-label Trial to Evaluate Safety of the House Dust Mite (HDM) Sublingual Allergy Immunotherapy (SLIT) Tablet in Adolescent Subjects With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
Actual Study Start Date : September 23, 2020
Actual Primary Completion Date : April 24, 2021
Actual Study Completion Date : April 24, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy
Drug Information available for: Odactra

Arm Intervention/treatment
Experimental: HDM SLIT Tablet
House dust mite (HDM) Sublingual allergy immunotherapy tablet
Biological: HDM SLIT-tablet
Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
Other Name: ACARIZAX, ODACTRA




Primary Outcome Measures :
  1. Treatment-emergent adverse event (TEAE) [ Time Frame: From time of first IMP administration and no later than 7 days after last IMP administration, approximately 35 days. ]
    Number and proportion of subjects with at least one TEAE, as well as number of events.


Secondary Outcome Measures :
  1. Solicited TEAE [ Time Frame: From time of first IMP administration and no later than 7 days after last IMP administration, approximately 35 days. ]
    Number and proportion of subjects with at least one solicited TEAE, as well as number of events.

  2. IMP-related AE [ Time Frame: From time of first IMP administration and no later than 7 days after last IMP administration, approximately 35 days. ]
    Number and proportion of subjects with at least one IMP-related AE, as well as number of events.

  3. Treatment-emergent serious adverse events (SAE) [ Time Frame: From time of first IMP administration and no later than 7 days after last IMP administration, approximately 35 days. ]
    Number and proportion of subjects with at least one treatment-emergent SAE, as well as number of events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent
  • Male or female subjects aged ≥12 to ≤17 years
  • A clinical history of allergic rhinitis/rhinoconjunctivitis (AR/C) when exposed to HDM
  • Positive skin prick test (SPT) to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae at screening
  • Lung function measured by Forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted value or according to local requirements while on subject's usual asthma medication
  • The subject must be willing and able to comply with trial protocol and adhere to IMP treatment

Main Exclusion Criteria:

  • A subject who has previously been included in studies with the HDM SLIT-tablet, or otherwise being treated with the marketed HDM SLIT-tablet (e.g. ACARIZAX, ODACTRA)
  • Any SLIT or SCIT treatment with D. pteronyssinus or D. farinae reaching the maintenance dose within the last 5 years. In addition, any SLIT or SCIT treatment with D. pteronyssinus or D. farinae within the previous 12 months prior to visit 1
  • Ongoing treatment with any allergy immunotherapy product at screening
  • Severe chronic oral inflammation
  • A diagnosis or history of eosinophilic oesophagitis
  • Any clinical deterioration of asthma that resulted in emergency treatment, hospitalisation or treatment with systemic corticosteroids within 3 months prior to first tablet administration
  • Female with positive urine pregnancy test, breastfeeding, pregnant or planning to become pregnant within the projected duration of the trial
  • Sexually active female of childbearing potential without medically accepted contraceptive method

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04541004


Locations
Show Show 27 study locations
Sponsors and Collaborators
ALK-Abelló A/S
Syneos Health
Investigators
Layout table for investigator information
Principal Investigator: Andreas Horn, MD HNO Praxis am Neckar
Layout table for additonal information
Responsible Party: ALK-Abelló A/S
ClinicalTrials.gov Identifier: NCT04541004    
Other Study ID Numbers: MT-18
2020-000446-34 ( EudraCT Number )
First Posted: September 9, 2020    Key Record Dates
Last Update Posted: July 19, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by ALK-Abelló A/S:
Allergic rhinitis
House dust mite
Adolescent
Pediatric
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Respiratory Tract Infections
Infections
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Hypersensitivity
Immune System Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate